Exclusive Journals Coverage

Exclusive Journals Coverage articles provide quick insight and additional author perspectives on select studies recently published in Journal of Clinical Oncology and Journal of Oncology Practice.

Mar 16, 2015
Among patients with prostate cancer being treated with continuous (non-intermittent) androgen deprivation therapy, those whose testosterone dipped to a nadir of less than 20 nanograms per deciliter within the first year of treatment experienced improved survival and . . .
Mar 09, 2015
For children and adolescents being treated for acute lymphoblastic leukemia, those who receive a stem-cell transplant from an unrelated donor have the same overall survival as those who receive the transplant from a sibling. 
Mar 02, 2015
"The study found that over a 14-week period, incidence of HFSR—of any grade—was lower among patients who started using the urea-based cream at the start of treatment, compared to patients who received best supportive care alone." 
Feb 23, 2015
According to first author, Dirk Schadendorf, MD, the study is “The first meta-analysis looking at Ipilimumab. It is also the largest analysis of melanoma patients ever conducted, with close to 5000 patients  . . ."
Feb 09, 2015
“The question this study asked was: Can you end up transcending the poor prognosis associated with widespread disease distribution by using radical surgery to ultimately leave that person with no disease after you've finished? . . ."
Feb 02, 2015
A new study in the Journal of Oncology Practice (JOP) set out to see how often fertility discussions were being documented in eligible patients’ charts.
Jan 26, 2015
"Often people have many questions and fears about the radiotherapy machine and treatment in general. Physicians . . . know that if the patient is anxious, there’s a strong chance it will continue throughout the therapy. It might even have clinical impact in that  . . ."
Jan 12, 2015
"The phase II study found that patients who received the immunotherapy GVAX—which is administered with cyclophosphamide—plus immunotherapy CRS-207 had a significantly longer overall survival (OS) of 6.1 months, compared to an OS of 3.9 month among patients who received GVAX alone . . ."
Jan 05, 2015
A study in the Journal of Oncology Practice identified several building blocks that are essential in shifting a cancer center towards a more interdisciplinary model [and] offers a blueprint for other hospitals that wish to start multidisciplinary clinics.
Jan 05, 2015
By Larissa Nekhlyudov, MD, MPH, and Ann Partridge, MD, MPH, Dana-Farber Cancer Institute, Harvard Medical School